Dataset Viewer
name
stringlengths 8
13
| light_chain_class
stringclasses 2
values | type
stringclasses 5
values | original_mab_isotype_or_format
stringclasses 17
values | clinical_status
stringclasses 3
values | phagec
bool 2
classes | year_name_proposed
int64 1.99k
2.01k
| metadata_notes
stringclasses 3
values | vh
stringlengths 112
130
| vl
stringlengths 104
113
| lc_class
stringclasses 2
values | source
stringclasses 3
values | source_detaileda
stringlengths 4
9
| disclaimers_and_known_issues
nullclasses 6
values | sequence_info_notes
stringclasses 1
value | hek_titer_mg_l
float64 6.58
277
| fab_tm_by_dsf_deg_c
float64 59.5
91.5
| sgac_sins_as100_nh4_2so4_mm
float64 0
1k
| hic_retention_time_min_a
float64 8.47
25
| smac_retention_time_min_a
float64 8.49
25
| slope_for_accelerated_stability
float64 -0.01
1.27
| poly_specificity_reagent_psr_smp_score_0_1
float64 0
0.81
| affinity_capture_self_interaction_nanoparticle_spectroscopy_ac_sins_delta_lambda_max_nm_average
float64 -1.08
29.9
| cic_retention_time_min
float64 8.26
13.5
| csi_bli_delta_response_nm
float64 -0.05
0.6
| elisa
float64 0.89
14.5
| bvp_elisa
float64 1.03
22.7
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
abituzumab
|
kappa
|
ZU
|
IgG2
|
Phase 2
| false
| 2,013
|
a Made with human isotype
|
QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL109
| null |
aPL and RL refer to WHO-INN publications for proposed and recommended lists
| 89.555458
| 75.5
| 900
| 9.227
| 8.725
| 0.05563
| 0.166666
| 1.458861
| 8.621
| 0
| 1.137375
| 2.720799
|
abrilumab
|
kappa
|
HU
|
IgG2
|
Phase 2
| false
| 2,014
|
b Mixed chimeric, humanized LC and HC
|
QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS
|
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL111
| null | null | 100.223196
| 71
| 900
| 9.413
| 8.699
| 0.02829
| 0
| -0.928526
| 8.384
| -0.02
| 1.124624
| 1.818303
|
adalimumab
|
kappa
|
HU
|
IgG1
|
Approved
| true
| 1,999
|
c Most as those molecules labeled Yes in the phage column were discovered and or optimized by phage display. A small number of these were optimized by fragment-based phage techniques not involving display.
|
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK
|
kappa
|
PDB
|
4NYL
| null | null | 134.928638
| 71
| 900
| 8.816
| 8.672
| 0.05069
| 0
| 1.062328
| 8.865
| -0.01
| 1.075515
| 1.488186
|
alemtuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,000
| null |
QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK
|
kappa
|
PDB
|
1BEY
| null | null | 144.653543
| 74.5
| 1,000
| 8.769
| 8.672
| 0.06431
| 0
| -0.789199
| 8.514
| -0.02
| 1.161491
| 1.464226
|
alirocumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,012
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS
|
DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 69.232345
| 71.5
| 900
| 9.036
| 8.681
| 0.0292
| 0
| 1.230511
| 8.757
| -0.01
| 1.196224
| 2.1797
|
anifrolumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| false
| 2,013
| null |
EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK
|
kappa
|
WHO-INN
|
PL109
| null | null | 82.046821
| 62.5
| 700
| 8.799
| 8.629
| 0.0708
| 0
| -0.561397
| 8.489
| -0.02
| 1.15745
| 1.623295
|
atezolizumab
|
kappa
|
ZU
|
IgG1-no-glyco
|
Approved
| true
| 2,014
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL112
| null | null | 164.085804
| 73.5
| 300
| 13.353
| 19.283
| 0.0556
| 0.065812
| 14.971122
| 10.76
| 0.06
| 1.294746
| 6.197378
|
bapineuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false
| 2,005
| null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS
|
DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK
|
kappa
|
US Patent
|
US7582733
| null | null | 151.09165
| 73
| 1,000
| 8.855
| 8.655
| 0.07017
| 0
| -0.734256
| 8.619
| 0.06
| 1.20895
| 3.548752
|
basiliximab
|
kappa
|
XI
|
IgG1
|
Approved
| false
| 1,996
| null |
QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS
|
QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK
|
kappa
|
PDB
|
1MIM
| null | null | 107.461588
| 60.5
| 0
| 9.578
| 8.576
| 0.0476
| 0.397164
| 28.757059
| 9.449
| 0
| 1.201328
| 2.138577
|
bavituximab
|
kappa
|
XI
|
IgG1
|
Phase 3
| false
| 2,006
| null |
EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS
|
DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK
|
kappa
|
WHO-INN
|
PL95
| null | null | 45.110274
| 59.5
| 0
| 11.499
| 12.689
| 0.0404
| 0.557037
| 29.851202
| 11.395
| -0.01
| 1.315456
| 1.692884
|
belimumab
|
lambda
|
HU
|
IgG1
|
Approved
| true
| 2,003
| null |
QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS
|
SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL
|
lambda
|
US Patent
|
US8101181
| null | null | 10.472727
| 60
| 800
| 10.461
| 9.267
| 0.1304
| 0
| 0.771252
| 8.588
| -0.03
| 3.609535
| 12.228952
|
benralizumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false
| 2,009
| null |
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL102
| null | null | 146.712684
| 76
| 800
| 9.467
| 9.09
| 0.0243
| 0.353712
| 5.977933
| 9.628
| -0.01
| 1.231263
| 1.424719
|
bevacizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,000
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
|
kappa
|
PDB
|
1BJ1
| null | null | 49.978578
| 63.5
| 700
| 11.772
| 11.07
| 0.2198
| 0
| 0.79022
| 9.822
| -0.02
| 1.285914
| 2.784692
|
bimagrumab
|
lambda
|
HU
|
IgG1
|
Phase 3
| true
| 2,012
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS
|
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL108
| null | null | 150.238851
| 72
| 0
| 10.125
| 8.829
| 0.09126
| 0.696556
| 29.645095
| 12.328
| 0.1
| 1.548608
| 5.327787
|
blosozumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 2
| true
| 2,011
| null |
QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 120.009752
| 70.5
| 600
| 9.241
| 8.626
| 0.1252
| 0.208243
| 11.472476
| 8.866
| 0.46
| 13.177765
| 12.84792
|
bococizumab
|
kappa
|
ZU
|
IgG2
|
Phase 3
| true
| 2,013
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL110
| null | null | 95.786921
| 67
| 0
| 10.179
| 9.108
| 0.067
| 0.760184
| 29.645095
| 10.595
| 0.5
| 13.496458
| 18.877205
|
brentuximab
|
kappa
|
XI
|
IgG1-ADC
|
Approved
| false
| 2,010
| null |
QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA
|
DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 268.061982
| 72
| 800
| 10.535
| 8.683
| -0.003086
| 0.247488
| -0.542427
| 8.551
| -0.03
| 4.2116
| 2.242928
|
briakinumab
|
lambda
|
HU
|
IgG1
|
Phase 3
| true
| 2,009
| null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS
|
QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL
|
lambda
|
WHO-INN
|
PL101
| null | null | 121.992234
| 71.5
| 0
| 9.359
| 8.737
| 0.1054
| 0.556059
| 29.645095
| 10.394
| 0.02
| 4.829996
| 10.217637
|
brodalumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false
| 2,011
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS
|
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 150.862586
| 74.5
| 900
| 9.079
| 8.743
| 0.01717
| 0.26549
| 11.207609
| 8.971
| -0.01
| 1.475125
| 2.92579
|
canakinumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,007
| null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS
|
EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK
|
kappa
|
US Patent
|
US8105587
| null | null | 45.724929
| 72
| 800
| 9.321
| 8.727
| 0.03791
| 0
| 0.669938
| 8.635
| 0
| 1.195418
| 2.545757
|
carlumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| true
| 2,010
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 243.323478
| 69.5
| 700
| 11.167
| 9.31
| 0.07491
| 0.211582
| -0.438032
| 8.62
| -0.02
| 2.761083
| 8.879201
|
certolizumab
|
kappa
|
ZU
|
FabPEG
|
Approved
| false
| 2,004
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK
|
kappa
|
US Patent
|
US7402662
| null | null | 186.709369
| 81.5
| 500
| 11.478
| 10.815
| 0.04289
| 0
| 0.163095
| 9.314
| -0.01
| 1.143818
| 1.64792
|
cetuximab
|
kappa
|
XI
|
IgG1
|
Approved
| false
| 1,999
| null |
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA
|
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK
|
kappa
|
PDB
|
1YY8
| null | null | 109.160445
| 68.5
| 400
| 10.11
| 8.91
| 0.05474
| 0
| 1.299961
| 8.906
| -0.04
| 1.09328
| 1.085524
|
cixutumumab
|
lambda
|
HU
|
IgG1
|
Phase 2
| true
| 2,008
| null |
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS
|
SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL100
| null | null | 154.25963
| 73.5
| 0
| 11.76
| 10.723
| 0.1617
| 0.657024
| 29.645095
| 9.664
| 0.38
| 3.766344
| 11.90416
|
clazakizumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,012
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS
|
AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 113.477347
| 69.5
| 800
| 9.568
| 8.871
| 0.05306
| 0
| 0.930046
| 8.729
| -0.03
| 1.281554
| 4.115141
|
codrituzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,013
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS
|
DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL109
| null | null | 66.347408
| 73
| 1,000
| 8.836
| 8.592
| 0.255
| 0.147987
| -0.285719
| 8.454
| -0.01
| 9.418865
| 14.874542
|
crenezumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 3
| false
| 2,011
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS
|
DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 149.265977
| 72
| 700
| 10.031
| 8.703
| 0.04786
| 0.104936
| 6.3708
| 8.899
| 0
| 1.133396
| 2.780699
|
dacetuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,007
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL98
| null | null | 128.452216
| 68
| 1,000
| 8.466
| 8.614
| 0.0033
| 0
| -0.014676
| 8.467
| -0.04
| 1.079326
| 1.335206
|
daclizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 1,994
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS
|
DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK
|
kappa
|
PDB
|
3NFP
| null | null | 245.107923
| 74
| 900
| 9.286
| 8.751
| 0.02794
| 0
| -0.110586
| 8.476
| -0.02
| 1.180366
| 1.414309
|
dalotuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,009
| null |
QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS
|
DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK
|
kappa
|
US Patent
|
US7914784
| null | null | 82.41734
| 77
| 800
| 9.891
| 8.704
| 0.1466
| 0.399648
| 13.68059
| 9.118
| 0.14
| 2.898655
| 8.253577
|
daratumumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,009
| null |
EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 233.334298
| 71
| 800
| 9.514
| 8.926
| 0.06363
| 0
| 1.80923
| 8.855
| 0
| 1.213584
| 3.151414
|
denosumab
|
kappa
|
HU
|
IgG2
|
Approved
| false
| 2,005
| null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK
|
kappa
|
US Patent
|
US7364736
| null | null | 134.167846
| 69.5
| 1,000
| 8.501
| 8.603
| 0.01043
| 0
| 5.907925
| 8.811
| 0.11
| 5.917966
| 17.74975
|
dinutuximab
|
kappa
|
XI
|
IgG1
|
Approved
| false
| 2,013
| null |
EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS
|
EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
|
kappa
|
WHO-INN
|
PL109
| null | null | 76.42882
| 69
| 800
| 9.833
| 8.963
| 0.0098
| 0.302741
| 3.635206
| 9.405
| -0.02
| 1.030887
| 1.69176
|
drozitumab
|
lambda
|
HU
|
IgG1
|
Phase 2
| true
| 2,010
| null |
EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS
|
SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL103
| null | null | 22.068896
| 63
| 0
| 9.29
| 8.716
| 0.02829
| 0
| 29.645095
| 8.79
| 0.04
| 1.096797
| 1.479534
|
duligotuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true
| 2,012
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 192.582804
| 67.5
| 0
| 10.206
| 8.938
| 0.05514
| 0.33444
| 29.645095
| 9.53
| 0.6
| 8.539748
| 9.630616
|
dupilumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 3
| false
| 2,012
| null |
EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS
|
DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL108
| null | null | 163.549147
| 76.5
| 700
| 10.159
| 9.009
| 0.02874
| 0.146876
| 10.804212
| 9.752
| -0.01
| 8.694358
| 19.270549
|
eculizumab
|
kappa
|
ZU
|
IgG24
|
Approved
| false
| 2,002
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
|
kappa
|
US Patent
|
US6355245
| null | null | 226.468532
| 66
| 700
| 10.41
| 9.277
| 0.008
| 0
| 0.043333
| 8.499
| -0.04
| 0.959428
| 2.995506
|
efalizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,001
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK
|
kappa
|
PDB
|
3EOA
| null | null | 166.992344
| 72.5
| 900
| 8.668
| 8.641
| 0
| 0
| 0.681276
| 8.542
| -0.02
| 0.98291
| 1.238202
|
eldelumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false
| 2,013
| null |
QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK
|
kappa
|
WHO-INN
|
PL109
| null | null | 89.253053
| 59.5
| 500
| 12.422
| 25
| 0.0998
| 0
| 1.21252
| 10.156
| -0.02
| 1.109093
| 1.747088
|
elotuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,008
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 213.1906
| 83.5
| 700
| 10.314
| 9.288
| 0
| 0
| -0.224469
| 8.469
| -0.03
| 0.978042
| 1.264794
|
emibetuzumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 2
| true
| 2,014
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL111
| null | null | 98.748918
| 71.5
| 0
| 9.638
| 8.684
| 0.04114
| 0.643143
| 29.645095
| 9.528
| 0.06
| 3.300083
| 8.329451
|
enokizumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true
| 2,010
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 239.819013
| 68
| 600
| 12.934
| 10.881
| 0.08966
| 0.125828
| 1.533553
| 9.028
| -0.02
| 1.173417
| 3.239268
|
epratuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false
| 1,999
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS
|
DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK
|
kappa
|
US Patent
|
US5789554
| null | null | 78.230572
| 65
| 900
| 9.189
| 8.629
| 0.02629
| 0.130915
| 3.014187
| 8.689
| -0.01
| 1.474552
| 2.342762
|
etrolizumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true
| 2,010
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 173.842456
| 76
| 900
| 9.322
| 8.77
| 0.2009
| 0.420378
| 2.017646
| 8.768
| -0.03
| 2.182071
| 4.228952
|
evolocumab
|
lambda
|
HU
|
IgG2
|
Approved
| false
| 2,012
| null |
EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS
|
ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL108
| null | null | 260.677128
| 65
| 700
| 10.355
| 9.13
| 0.0298
| 0.204333
| 2.236431
| 9.254
| -0.01
| 1.754453
| 1.754409
|
farletuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false
| 2,008
| null |
EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS
|
DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 220.817624
| 75.5
| 800
| 9.491
| 9.065
| 0.006029
| 0
| -0.501925
| 8.687
| -0.01
| 1.073797
| 1.321797
|
fasinumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 3
| false
| 2,012
| null |
QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS
|
DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 110.374487
| 71
| 900
| 10.026
| 8.715
| 0.06657
| 0
| -0.671927
| 8.359
| -0.02
| 1.156861
| 2.527121
|
fezakinumab
|
lambda
|
HU
|
IgG1
|
Phase 2
| true
| 2,009
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS
|
QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL
|
lambda
|
WHO-INN
|
PL101
| null | null | 141.453494
| 69
| 600
| 11.798
| 13.709
| 0.06932
| 0.264712
| 2.50184
| 11.26
| -0.0158
| 1.145613
| 2.146423
|
ficlatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,011
| null |
QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS
|
DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 249.025765
| 75
| 900
| 9.421
| 8.882
| 0.04614
| 0
| -0.893786
| 8.488
| -0.02
| 1.133884
| 1.233278
|
figitumumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false
| 2,008
| null |
EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS
|
DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 119.916768
| 66.5
| 0
| 10.745
| 9.86
| 0.06446
| 0.378958
| 29.645095
| 10.533
| 0.02
| 2.893762
| 5.650582
|
fletikumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 2
| false
| 2,013
| null |
QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS
|
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL110
| null | null | 220.376225
| 71.5
| 700
| 11.038
| 9.143
| 0.01897
| 0
| -0.125458
| 8.474
| -0.02
| 1.024451
| 1.408319
|
foralumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false
| 2,010
| null |
QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 174.435088
| 66
| 0
| 9.842
| 8.574
| 0.03766
| 0.371715
| 28.085284
| 9.324
| 0
| 4.767634
| 4.711481
|
fresolimumab
|
kappa
|
HU
|
IgG4
|
Phase 2
| true
| 2,009
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS
|
ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 166.036557
| 74
| 700
| 10.875
| 9.145
| 0.05526
| 0
| -0.515083
| 8.466
| -0.02
| 1.300181
| 3.512812
|
fulranumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false
| 2,010
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS
|
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 142.018924
| 68.5
| 900
| 9.328
| 9.342
| 0.07229
| 0.187679
| 11.560721
| 9.346
| 0
| 1.849308
| 6.923128
|
galiximab
|
lambda
|
XI
|
IgG1
|
Phase 2
| false
| 2,003
| null |
QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS
|
ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL
|
lambda
|
US Patent
|
US6113898
| null | null | 174.116872
| 67.5
| 600
| 12.198
| 14.77
| 0.03135
| 0
| 1.093714
| 8.87
| -0.02
| 1.213663
| 3.810316
|
ganitumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| true
| 2,010
| null |
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS
|
DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 229.43987
| 78.5
| 800
| 9.334
| 8.77
| 0.01174
| 0.552845
| 4.774833
| 9.482
| -0.01
| 1.295156
| 4.907155
|
gantenerumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| true
| 2,007
| null |
QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS
|
DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL97
| null | null | 162.659011
| 77.5
| 1,000
| 9.004
| 8.487
| 0.06671
| 0.5526
| 6.957989
| 8.709
| 0.1
| 13.82019
| 22.74609
|
gemtuzumab
|
kappa
|
ZU
|
IgG4-ADC
|
Approved
| false
| 2,000
| null |
EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS
|
DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK
|
kappa
|
US Patent
|
US5773001
| null | null | 171.299785
| 72.5
| 500
| 12.259
| 13.931
| 0.04534
| 0
| 1.020051
| 9.106
| -0.01
| 1.080084
| 1.697837
|
gevokizumab
|
kappa
|
ZU
|
IgG2
|
Phase 3
| false
| 2,010
| null |
QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS
|
DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 136.360641
| 71.5
| 1,000
| 8.828
| 8.607
| 0.07129
| 0
| -0.51477
| 8.579
| -0.03
| 1.18008
| 1.931448
|
girentuximab
|
kappa
|
XI
|
IgG1
|
Phase 3
| false
| 2,009
| null |
DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS
|
DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 30.72183
| 63
| 1,000
| 9.081
| 8.683
| 0.03154
| 0
| -0.751821
| 8.524
| -0.04
| 1.090143
| 1.393677
|
glembatumumab
|
kappa
|
HU
|
IgG2
|
Phase 2
| false
| 2,009
| null |
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS
|
EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL102
| null | null | 152.712345
| 70.5
| 0
| 13.68
| 25
| 0.303
| 0.166107
| 28.880635
| 13.5
| 0.01
| 1.063291
| 2.215356
|
golimumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,004
| null |
QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK
|
kappa
|
US Patent
|
US7250165
| null | null | 163.238323
| 70
| 0
| 11.359
| 12.747
| 0.06274
| 0.234008
| 22.965397
| 11.23
| -0.01
| 1.309296
| 2.712146
|
guselkumab
|
lambda
|
HU
|
IgG1
|
Phase 3
| true
| 2,013
| null |
EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS
|
QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL109
| null | null | 167.340129
| 69.5
| 700
| 11.403
| 9.195
| 0.1931
| 0.469339
| 3.367196
| 10.109
| 0.02
| 1.541176
| 5.867554
|
ibalizumab
|
kappa
|
ZU
|
IgG4
|
Phase 3
| false
| 2,007
| null |
QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS
|
DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL97
| null | null | 133.282633
| 72
| 800
| 10.237
| 9.771
| 0.0393
| 0
| -0.339304
| 8.66
| -0.03
| 0.993142
| 1.126217
|
imgatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,012
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 187.708497
| 71.5
| 800
| 10.09
| 8.898
| 0.06543
| 0
| 0.893874
| 8.994
| -0.01
| 5.014941
| 11.774376
|
infliximab
|
kappa
|
XI
|
IgG1
|
Approved
| false
| 1,997
| null |
EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS
|
DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK
|
kappa
|
PDB
|
4G3Y
| null | null | 6.581146
| 64.5
| 0
| 10.36
| 8.888
| 0.1812
| 0
| 29.645095
| 9.011
| 0.05
| 1.036832
| 1.371714
|
inotuzumab
|
kappa
|
ZU
|
IgG4-ADC
|
Phase 3
| false
| 2,004
| null |
EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS
|
DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK
|
kappa
|
US Patent
|
US7355011
| null | null | 169.767062
| 83
| 800
| 9.717
| 9.052
| 0.02517
| 0.250008
| 4.029671
| 9.295
| 0.01
| 3.180205
| 5.395674
|
ipilimumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,005
| null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
|
kappa
|
US Patent
|
US6984720
| null | null | 169.561868
| 73
| 400
| 11.57
| 12.981
| 0.03963
| 0.229631
| 10.413099
| 10.941
| 0.01
| 1.052425
| 1.691847
|
ixekizumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Approved
| true
| 2,011
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS
|
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 97.277433
| 83
| 500
| 10.936
| 9.082
| 0.1614
| 0.809817
| 19.952343
| 9.636
| 0.11
| 8.79746
| 10.398669
|
lampalizumab
|
kappa
|
ZU
|
Fab
|
Phase 3
| false
| 2,012
| null |
EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS
|
DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 187.075402
| 67
| 800
| 9.25
| 8.765
| 0.08749
| 0
| 0.494177
| 8.455
| -0.03
| 1.108848
| 1.340433
|
lebrikizumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 3
| false
| 2,009
| null |
QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
|
DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 61.607125
| 66
| 500
| 12.381
| 15.71
| 0.0047
| 0
| 0.255326
| 9.071
| -0.04
| 0.962254
| 1.45618
|
lenzilumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| true
| 2,014
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
|
EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL111
| null | null | 184.742758
| 74
| 0
| 8.722
| 8.605
| 0.03277
| 0.655128
| 29.645095
| 10.122
| 0.02
| 14.459031
| 19.604659
|
lintuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false
| 1,996
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK
|
kappa
|
US Patent
|
US5530101
| null | null | 229.970848
| 75.5
| 700
| 10.874
| 9.428
| 0.048
| 0
| 0.885988
| 8.933
| -0.02
| 1.045706
| 1.254576
|
lirilumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 2
| false
| 2,012
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS
|
EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 270.480297
| 70
| 300
| 25
| 25
| 0.00174
| 0.182914
| 20.998948
| 10.562
| 0.04
| 1.269556
| 3.549418
|
lumiliximab
|
kappa
|
XI
|
IgG1
|
Phase 2
| false
| 2,004
| null |
EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK
|
kappa
|
US Patent
|
US6893636
| null | null | 86.273039
| 64.5
| 800
| 9.545
| 8.782
| 0.06686
| 0.144897
| 1.443549
| 8.815
| -0.02
| 1.137911
| 2.218303
|
matuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,003
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK
|
kappa
|
PDB
|
3C08
| null | null | 224.328821
| 72
| 900
| 9.84
| 8.834
| 0.0164
| 0
| -0.927208
| 8.635
| -0.03
| 1.059855
| 1.027621
|
mavrilimumab
|
lambda
|
HU
|
IgG4
|
Phase 2
| true
| 2,009
| null |
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS
|
QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL102
| null | null | 150.548853
| 68.5
| 700
| 10.296
| 8.671
| 0.04903
| 0
| -0.778754
| 8.496
| -0.01
| 1.213082
| 2.16173
|
mepolizumab
|
kappa
|
ZU
|
IgG1AA-mut
|
Approved
| false
| 1,999
| null |
QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS
|
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK
|
kappa
|
US Patent
|
US5693323
| null | null | 221.475177
| 78.5
| 900
| 9.238
| 8.816
| 0.04451
| 0
| -0.956637
| 8.408
| -0.04
| 1.131191
| 1.051581
|
mogamulizumab
|
kappa
|
ZU
|
IgG1-glyco
|
Approved
| false
| 2,010
| null |
EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS
|
DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 89.767929
| 68.5
| 800
| 9.641
| 8.82
| 0.03631
| 0
| -0.511762
| 8.631
| -0.02
| 1.118282
| 2.165724
|
motavizumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| true
| 2,006
| null |
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS
|
DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK
|
kappa
|
PDB
|
3IXT
| null | null | 133.551595
| 86
| 800
| 9.689
| 8.82
| 0.04454
| 0
| 2.522763
| 8.66
| -0.01
| 1.22954
| 5.360399
|
muromonab
|
kappa
|
XIa
|
IgG2a
|
Approved
| false
| 1,988
| null |
QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
|
QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIK
|
kappa
|
PDB
|
1SY6
| null | null | 113.52288
| 74.5
| 1,000
| 8.899
| 8.578
| 0.03829
| 0.175892
| 2.311513
| 9.048
| 0.01
| 1.408897
| 3.937438
|
natalizumab
|
kappa
|
ZU
|
IgG4
|
Approved
| false
| 1,998
| null |
QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK
|
kappa
|
US Patent
|
US5840299
| null | null | 251.745705
| 79.5
| 900
| 9.7
| 8.843
| 0.01877
| 0
| 0.822884
| 8.764
| -0.01
| 1.063994
| 1.524792
|
necitumumab
|
kappa
|
HU
|
IgG1
|
Approved
| true
| 2,008
| null |
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS
|
EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 198.599891
| 76.5
| 600
| 10.807
| 9.9
| 0.0204
| 0
| 1.300578
| 8.771
| -0.02
| 1.045456
| 1.310483
|
nimotuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,005
| null |
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT
|
kappa
|
PDB
|
3GKW
| null | null | 15.13165
| 65.5
| 900
| 25
| 8.884
| 0.04357
| 0
| -0.585505
| 8.464
| -0.02
| 1.318679
| 3.424293
|
nivolumab
|
kappa
|
HU
|
IgG4-CPPC
|
Approved
| false
| 2,012
| null |
QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 178.809229
| 66
| 900
| 9.023
| 8.655
| 0.02743
| 0.135175
| 2.41804
| 8.853
| -0.01
| 1.153877
| 1.324459
|
obinutuzumab
|
kappa
|
ZU
|
IgG1-glyco
|
Approved
| false
| 2,009
| null |
QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
|
DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
|
kappa
|
WHO-INN
|
RL65
| null | null | 176.441448
| 73
| 600
| 10.641
| 8.964
| 0.0128
| 0.112785
| 1.831573
| 8.8
| -0.01
| 0.950558
| 1.629588
|
ocrelizumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false
| 2,005
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK
|
kappa
|
US Patent
|
US8562992
| null | null | 137.774414
| 70.5
| 300
| 9.911
| 8.83
| 0.0237
| 0
| 17.881994
| 9.532
| 0.01
| 1.128492
| 1.672659
|
ofatumumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,005
| null |
EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK
|
kappa
|
PDB
|
3GIZ
| null | null | 249.752167
| 68
| 800
| 9.729
| 9.524
| 0.02874
| 0
| 1.209699
| 9.248
| -0.02
| 1.122143
| 1.176705
|
olaratumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false
| 2,010
| null |
QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 141.936048
| 62.5
| 700
| 10.609
| 8.957
| 0.2885
| 0.483143
| 0.310395
| 9.417
| -0.02
| 1.316067
| 2.584359
|
olokizumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 2
| false
| 2,010
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 115.258271
| 69
| 700
| 9.908
| 8.973
| 0.04469
| 0
| -0.502615
| 8.749
| -0.03
| 1.105369
| 1.229285
|
omalizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,000
| null |
EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSLKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS
|
DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK
|
kappa
|
PDB
|
2XA8
| null | null | 150.447109
| 77.5
| 800
| 9.519
| 8.744
| 0.04511
| 0
| -0.438278
| 8.538
| -0.02
| 1.116105
| 1.166057
|
onartuzumab
|
kappa
|
ZU
|
IgG1-One-armed
|
Phase 3
| false
| 2,010
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 147.933138
| 80
| 800
| 9.919
| 8.869
| 0.04311
| 0
| -0.046662
| 8.911
| -0.02
| 1.119281
| 1.186689
|
otelixizumab
|
lambda
|
XIZUb
|
IgG1-no-glyco
|
Phase 3
| false
| 2,007
| null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS
|
DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL98
| null | null | 152.082453
| 75.5
| 1,000
| 9.082
| 8.72
| 0.08814
| 0
| 4.438287
| 8.719
| -0.02
| 1.127822
| 1.397671
|
otlertuzumab
|
kappa
|
ZU
|
scFv-Fc
|
Phase 2
| false
| 2,013
| null |
EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL110
| null | null | 149.600654
| 68.5
| 600
| 10.959
| 10.267
| 0.07229
| 0
| 2.260983
| 9.516
| -0.03
| 1.171753
| 1.781697
|
ozanezumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,012
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS
|
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL108
| null | null | 97.074688
| 67
| 0
| 10.034
| 8.632
| 0.05569
| 0.771314
| 27.692332
| 9.046
| 0.45
| 2.029358
| 4.452579
|
palivizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 1,998
| null |
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
|
DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK
|
kappa
|
US Patent
|
US7704505
| null | null | 243.119698
| 79.5
| 900
| 9.332
| 8.705
| 0.03666
| 0
| -0.852685
| 8.491
| -0.03
| 1.118847
| 2.876539
|
panitumumab
|
kappa
|
HU
|
IgG2
|
Approved
| false
| 2,004
| null |
QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS
|
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK
|
kappa
|
US Patent
|
US8628773
| null | null | 179.587857
| 78.5
| 900
| 9.479
| 8.799
| 0.03631
| 0
| -1.084605
| 8.42
| -0.03
| 1.062088
| 1.182696
|
panobacumab
|
kappa
|
HU
|
IgM
|
Phase 2
| false
| 2,008
| null |
EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS
|
DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 107.597686
| 69
| 900
| 9.827
| 8.85
| 0.02071
| 0
| -0.415577
| 8.992
| -0.01
| 1.212667
| 1.896839
|
parsatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true
| 2,012
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 40.019327
| 64.5
| 900
| 9.109
| 8.781
| 0.08654
| 0.134444
| 7.400359
| 8.651
| 0.12
| 10.046527
| 17.395674
|
patritumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| false
| 2,011
| null |
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS
|
DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL106
| null | null | 68.77442
| 71.5
| 600
| 10.15
| 9.321
| 0.05371
| 0.520073
| 13.086408
| 9.445
| 0.04
| 2.346217
| 4.34609
|
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 38